Related Experiment Video

Updated: Aug 7, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

The inhibition of platelet aggregation and blood coagulation by Micropechis ikaheka venom

I B Sundell1, R D Theakston, A S Kamiguti

  • 1Department of Haematology, University of Liverpool, Duncan Building, Daulby Street, Liverpool L69 3GA, UK. bsundell@liverpool.ac.uk

British Journal of Haematology
|September 21, 2001
PubMed

Insights

Micropechis ikaheka snake venom disrupts blood clotting by affecting platelets and endothelial cells. A specific phospholipase A2 (PLA2) enzyme in the venom is identified as a key factor in its anticoagulant effects.

Area of Science:

  • Biochemistry
  • Toxicology
  • Hematology

Background:

  • Snake venom toxins can cause severe bleeding by affecting blood coagulation.
  • Micropechis ikaheka envenoming primarily targets the nervous and muscular systems but also impacts hemostasis.

Purpose of the Study:

  • To investigate the effects of Micropechis ikaheka venom on platelets and endothelial cells.
  • To identify venom components responsible for hemostatic disturbances.

Main Methods:

  • Assessing venom effects on platelet aggregation induced by ADP and collagen.
  • Evaluating venom's impact on clotting assays involving platelet activation and endothelial tissue factor.
  • Fractionating venom and testing purified components, including a phospholipase A2 (PLA2).
  • Examining venom's effect on endothelial cell adhesion to extracellular matrix proteins.

Main Results:

  • M. ikaheka venom inhibited platelet aggregation and delayed clotting.
  • A 17 kDa fraction containing PLA2 was implicated in these anticoagulant effects.
  • An 11 kDa neurotoxin fraction also affected ADP-induced platelet aggregation.
  • The venom reduced endothelial cell adherence to vitronectin, fibronectin, and collagen.

Conclusions:

  • A 17 kDa PLA2 in M. ikaheka venom plays a significant role in its anticoagulant activity.
  • The venom interferes with platelet and endothelial cell procoagulant functions, contributing to bleeding risks.

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...